Pyridinium cross-links in multiple myeloma: Correlation with clinical parameters and use for monitoring of intravenous clodronate therapy - A pilot study of the German Myeloma Treatment Group (GMTG)

European Journal of Cancer Part A

Volumn 32, Issue 12, 1996, Pages 2053-2057

  Peest, D ^a   Deicher, H ^a   Fett, W ^a   Harms, P ^a   Braun, H J ^a   Planker, M ^a   Kindler, U ^a   Klinkenstein, C ^a   Schafer E ^a   Schumacher, K ^a   Siecke, H ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

bone resorption; clodronate; multiple myeloma; pyridinium cross links

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; COLLAGEN TYPE 1 TELOPEPTIDE; DEOXYPYRIDINOLINE; MELPHALAN; PREDNISONE; PYRIDINOLINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE DESTRUCTION; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MONITORING; MULTIPLE MYELOMA; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACIDS; BONE RESORPTION; CLODRONIC ACID; COLLAGEN; COLLAGEN TYPE I; HUMANS; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PARANEOPLASTIC SYNDROMES; PEPTIDES; PILOT PROJECTS; TUMOR MARKERS, BIOLOGICAL;

EID: 0030297676     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00228-6     Document Type: Article

References (28)

1. 1. Fleisch H. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 1991, 42, 919-944.
2. 2. Delmas PD, Charhon S, Chapuy MC, et al. Long-term effects of dichloromethylene diphosphonate (C12MDP) on skeletal lesions in multiple myeloma. Metab Bone Dis Relat Res 1982, 4, 163-168.
3. 3. Lahtinen R, Laakso M, Palva I, Virkkunen P, Elomaa I. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet 1992, 340, 1049-1052.
4. 4. Merlini Gg, Parrinello GA, Piccinini L, et al. Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy. Hematol Oncol 1990, 8, 23-30.
5. 5. Berenson J, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996, 334, 488-493.
6. 6. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer 1975, 36, 842-852.
7. 7. Durie BGM, Salmon SE, Mundy GR. Relation of osteoclast activating factor production to extent of bone disease in multiple myeloma. Br J Haematol 1981, 47, 21-30.
8. 8. Eyre D. New biomarkers of bone resorption (Editorial). J Clin Endocrinol Metab 1992, 74, 470A-470B.
9. 9. Risteli L, Risteli J. Biochemical markers of bone metabolism. Ann Med 1993, 25, 385-393.
10. 10. Uebelhart D, Gineyts E, Chapuy MC, Delmas PD. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Minerals 1990, 8, 87-96.
11. 11. Body JJ, Delmas PD. Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia. J Clin Endocrinol Metab 1992, 74, 471-475.
12. 12. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxyterminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 1993, 39, 635-640.
13. 13. Elomaa I, Virkkunen P, Risteli L, Risteli J. Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer 1992, 66, 337-341.
14. 14. Peest D, Deicher H, Coldewey R, et al. A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group. Eur J Cancer 1995, 31A, 146-151.
15. 15. Peest D, Coldewey R, Deicher H, et al. Prognostic value of clinical, laboratory, and histological characteristics in multiple myeloma: improved definition of risk groups. Eur J Cancer 1993, 29A, 978-983.
16. 16. Salmon SE, Wampler SE. Multiple myeloma: quantitative staging and assessment of response with a programmable pocket calculator. Blood 1977, 49, 379-389.
17. 17. Eyre DR, Koob TJ, Van-Ness KP. Quantitation of hydroxypyridinium crosslinks in collagen by high-performance liquid chromatography. Analyt Biochem 1984, 137, 380-388.
18. 18. Black D, Duncan A, Robins SP. Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography. Analyt Biochem 1988, 169, 197-203.
19. 19. Jurgovski E, Bethge H, Wiemann H. Zur Methodik der Laborbeurteilung im Hinblick auf die Verträglichkeit von Arzneimitteln. In Victor N, Dudeck J, Briszio EP, eds. Therapiestudien. Berlin, Heidelberg, New York, Springer Verlag, 1981, 478.
20. 20. Mundy GR, Raisz LG, Cooper RA, Schechter GP, Salmon SE. Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med 1974, 291, 1041-1046.
21. 21. Garret IR, Durie BGM, Nedwin GE, et al. Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. N Engl J Med 1987, 317, 526-532.
22. 22. Bartl R, Frisch B, Fateh-Moghadam A, Kettner G, Jaeger K, Sommerfeld W. Histologic classification and staging of multiple myeloma. Am J Clin Pathol 1987, 87, 342-355.
23. 23. Fritz E, Ludwig H, Kundi M. Prognostic relevance of cellular morphology in multiple myeloma. Blood 1984, 63, 1072-1079.
24. 24. Siris ES, Sherman WH, Baquiran DC, Schlatterer JP, Osserman EF, Canfield RE. Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma. N Engl J Med 1980, 302, 310-315.
25. 25. Delmas PD. Clinical use of biochemical markers of bone remodeling in osteoporosis. Bone 1992, 13 (Suppl. 1), S17-S21.
26. 26. Risteli L, Risteli J, Laakso M, et al. Clodronate has effects on osteoblasts and osteoclasts. Monitoring the effect using PINP and ICTP assays. Bone Minerals 1994, 25, S82-(Abstr.).
27. 27. Sahni M, Guenther HL, Fleisch H, Collins P, Martin TJ. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 1993, 91, 2004-2011.
28. 28. Roux C, Ravaud P, Cohen-Solal M, et al. Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone 1994, 15, 41-49.